New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 12, 2014
12:45 EDTELGX, ELGX, TRIV, TRIVJPMorgan hosts an analyst Medical Supplies & Devices/Industry conference call
Analyst Pasquale will discuss his initiation of coverage of Endologix (ELGX) and TriVascular Technologies (TRIV) in a conference call on May 12 at 1 pm.
News For ELGX;TRIV From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 21, 2014
07:16 EDTELGXEndologix trial results 'highly encouraging,' says Stifel
Subscribe for More Information
November 20, 2014
07:13 EDTELGXCanaccord to hold a forum
Subscribe for More Information
November 18, 2014
11:00 EDTELGXEndologix to host investor meeting
Subscribe for More Information
07:11 EDTELGXEndologix completes patient enrollment in Nellix EVAS FORWARD-IDE clinical trial
Endologix announced that it has completed patient enrollment in the EVAS FORWARD-IDE clinical trial, the company's U.S. pivotal clinical trial designed to evaluate the safety and effectiveness of the Nellix EndoVascular Aneurysm Sealing System for the endovascular repair of infrarenal abdominal aortic aneurysms, or AAA. Primary endpoint analysis results at one-year and beyond will be used to support the company's premarket approval, or PMA, application to the FDA for the Nellix EVAS System. The EVAS FORWARD-IDE clinical trial enrolled 179 patients at 29 centers in the U.S. and Europe. Enrollment under an extended investigation phase is anticipated to begin shortly and will continue during the pivotal trial follow-up period and PMA preparation/review process. Based on current assumptions and timelines, the company anticipates FDA approval of the Nellix System in the U.S. before the end of 2016.
November 13, 2014
07:30 EDTTRIVCredit Suisse to hold a conference
Healthcare Conference is being held in Scottsdale, Arizona on November 10-13 with webcasted company presentations to begin on November 13 at 11 am; not all company presentations may be webcasted. Webcast Link
November 11, 2014
08:36 EDTTRIVTriVascular growth trajectory intact, says Canaccord
Canaccord would be buyers of TriVascular, citing its strong top-line growth and gross margin expansion that the firm feels is not reflected in the stock's current valuation. The firm also sees strong clinician interest in the company's OVATION system. Canaccord reiterates its Buy rating and $19 price target on TriVascular shares.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use